DAX25.044 -0,9%Est506.060 -0,7%MSCI World4.343 -0,1%Top 10 Crypto8,5900 -2,2%Nas22.602 -0,7%Bitcoin56.723 +0,6%Euro1,1766 -0,2%Öl71,78 +2,1%Gold4.988 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 SAP 716460 Siemens Energy ENER6Y Airbus 938914 NVIDIA 918422 Deutsche Telekom 555750 Infineon 623100 Amazon 906866 Microsoft 870747 Lufthansa 823212 RENK RENK73 DroneShield A2DMAA Siemens 723610 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich tiefrot - aber über 25.000 Punkte -- Wall Street leichter -- Bayer profitiert von Trumps Glyphosat-Vorstoß -- Apple, Airbus, Amazon, Siemens Energy, Microsoft, Figma, eBay, SAP im Fokus
Top News
Rohstoffe: Aktueller Marktbericht zu Gold, Öl & Co. Rohstoffe: Aktueller Marktbericht zu Gold, Öl & Co.
Börse am Donnerstag: DAX letztlich tiefrot - 25.000-Punkte-Marke nach Rücksetzer zurückerobert Börse am Donnerstag: DAX letztlich tiefrot - 25.000-Punkte-Marke nach Rücksetzer zurückerobert
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Eupraxia Pharmaceuticals Aktie

Kaufen
Verkaufen
6,30 EUR -0,30 EUR -4,55 %
STU
7,82 USD -0,34 USD -4,17 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.353,32 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EGRS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCA29842P1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolEPRX

Eupraxia Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireEupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireEupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
finanzen.netEupraxia Pharmaceuticals veröffentlichte Zahlen zum vergangenen Quartal
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR NewswireEupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
PR NewswireEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
PR NewswireEupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
PR NewswireEupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
PR NewswireEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
PR NewswireEupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
PR NewswireEupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
PR NewswireEupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
PR NewswireEupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
PR NewswireEupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
PR NewswireEupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
PR NewswireEupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
PR NewswireEupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
finanzen.netEupraxia Pharmaceuticals präsentierte Bilanzzahlen zum jüngsten Jahresviertel
PR NewswireEupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireEupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireEupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
PR NewswireEupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
PR NewswireEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
PR NewswireEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
PR NewswireEupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
PR NewswireEupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
finanzen.netEupraxia Pharmaceuticals legte die Bilanz zum abgelaufenen Quartal vor

Eupraxia Pharmaceuticals News

Eupraxia Pharmaceuticals News: auf dieser Seite finden Sie alle Eupraxia Pharmaceuticals News und Nachrichten zur Eupraxia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eupraxia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eupraxia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.